News articles about Dova Pharmaceuticals (NASDAQ:DOVA) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.908618709386 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research analysts have recently issued reports on DOVA shares. Zacks Investment Research lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Jefferies Group increased their target price on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Finally, Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a research report on Tuesday, September 26th.
Dova Pharmaceuticals (NASDAQ:DOVA) opened at $29.86 on Friday. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $30.92.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same period in the previous year, the company earned ($0.41) earnings per share. equities research analysts predict that Dova Pharmaceuticals will post -1.51 EPS for the current fiscal year.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dova Pharmaceuticals (DOVA) Share Price” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-dova-pharmaceuticals-dova-share-price.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.